Patents by Inventor Brendan Larder
Brendan Larder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8574831Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: GrantFiled: November 1, 2007Date of Patent: November 5, 2013Assignee: Virco N.V.Inventors: Pascale Alfons Rosa Dehertogh, Kurt Hertogs, Brendan Larder, Dechao Wang
-
Patent number: 8563236Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: GrantFiled: January 13, 2009Date of Patent: October 22, 2013Assignee: Virco, N.V.Inventors: Kurt Hertogs, Brendan Larder, Rudi Pauwels
-
Publication number: 20090162867Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: ApplicationFiled: January 13, 2009Publication date: June 25, 2009Inventors: Kurt Hertogs, Brendan Larder, Rudl Pauwels
-
Patent number: 7494768Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: GrantFiled: May 30, 2000Date of Patent: February 24, 2009Assignee: Tibotec-Virco Virology BVBAInventors: Kurt Hertogs, Brendan Larder, Rudi Pauwels
-
Publication number: 20080286754Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: ApplicationFiled: November 1, 2007Publication date: November 20, 2008Inventors: Pascale Alfons Rosa DEHERTOGH, Kurt Hertogs, Brendan Larder, Dechao Wang
-
Publication number: 20070287834Abstract: The present invention relates to a method for mutation analysis of the HIV pol gene of HIV-1 virions comprising amplifying virion RNA or DNA via nested PCR using outer primers as represented in SEQ ID No. 1 and 2, amplifying said PCR product via nested PCR using a 5? and 3? primer chosen from the inner primers SEQ ID No. 3, 4, 5 and 6, and sequencing this secondary obtained PCR product using at least one sequencing primer chosen from any of SEQ ID No. 7 to 12 or variants thereof. In the alternative, at least one secondary sequencing primer may be used chosen from any of SEQ ID No. 13 to 24. The present invention also relates to kits for performing such a method as well as primers for performing the same.Type: ApplicationFiled: May 14, 2007Publication date: December 13, 2007Inventors: Brendan Larder, Sharon Kemp, Stuart Bloor, Ann Brophy
-
Patent number: 7292944Abstract: The present invention concerns methods and systems for improving the accuracy of predicting resistance of a disease to a therapy. In one embodiment of the invention, mean and standard deviation (SD) values of fold change in normalized sensitivity, relative to a laboratory wild type standard pathogen or malignant cell are calculated to demonstrate that the patient samples display inherently different degrees of variation in susceptibility to each therapy. In another embodiment, the 2×SD value for each therapy is used as the cut-off between sensitive (within normal susceptible range) and resistant (above normal susceptible range).Type: GrantFiled: October 22, 2001Date of Patent: November 6, 2007Assignee: Virco BVBAInventors: Brendan Larder, Richard P. Harrigan, Kurt Hertogs
-
Publication number: 20070166747Abstract: The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said sample is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, a distribution of sensitivities of one or more drugs suitable for treating a specific indication is determined.Type: ApplicationFiled: March 6, 2007Publication date: July 19, 2007Applicant: Virco N.V.Inventors: Brendan Larder, Stuart Bloor, Kurt Hertogs, Pascale Dehertogh, Rudy Mortier
-
Patent number: 7235387Abstract: The present invention relates to a method for mutation analysis of the HIV pol gene of HIV virions comprising amplifying virion RNA or DNA via nested PCR using outer primers as represented in SEQ ID No. 1 and 2, amplifying said PCR product via nested PCR using a 5? and 3? primer chosen from the inner primers SEQ ID No. 3, 4, 5, and 6, and sequencing this secondary obtained PCR product using at least one sequencing primer chosen from any of SEQ ID No. 7 to 12 or variants thereof. In the alternative, at least one secondary sequencing primer may be used chosen from any of SEQ ID No. 13 to 24. The benefit of the sequences present in the invention resides in the fact that, with the aid of the oligonucleotides, the sequences of all presently known HIV subtypes and all mutations of the pol gene presently known to yield resistance towards antiretroviral therapy can be determined. The present invention also relates to kits for performing such a method as well as primers for performing the same.Type: GrantFiled: April 20, 2001Date of Patent: June 26, 2007Assignee: Virco BVBAInventors: Brendan Larder, Sharon Kemp, Stuart Bloor, Ann Brophy
-
Patent number: 7206699Abstract: The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said sample is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, a distribution of sensitivities of one or more drugs suitable for treating a specific indication is determined.Type: GrantFiled: April 18, 2001Date of Patent: April 17, 2007Assignee: Virco N.V.Inventors: Brendan Larder, Stuart Bloor, Kurt Hertogs, Pascale Alfons Rosa Dehertogh, Rudy Jean Marc Mortier
-
Publication number: 20060246427Abstract: The present invention is directed to the field of HIV resistance to RT inhibitors and methods of determining the levels and mechanisms of action of HIV resistance. The methods of the present invention may be accomplished using a novel in vitro assay that provides a reaction well comprising a template for an HIV RT enzyme, a primer, a detectable dNTP substrate, an HIV RT inhibitor, and a ribonucleotide chosen from ATP and GTP or a pyrophosphate. The RT activity is determined by measuring the amount of the detectable dNTP substrate that is incorporated into the template, and the level and/or mechanism of resistance of HIV to the HIV RT inhibitor is determined using the RT activity. The methods may also be used for designing new therapies, screening for new drugs and treatments, and determining the role of mutations in observed resistance.Type: ApplicationFiled: May 31, 2006Publication date: November 2, 2006Inventors: Johan Lennerstrand, Brendan Larder
-
Patent number: 7087375Abstract: The present invention is directed to the field of HIV resistance to RT inhibitors and methods of determining the levels and mechanisms of action of HIV resistance. The methods of the present invention may be accomplished using a novel in vitro assay that provides a reaction well comprising a template for an HIV RT enzyme, a primer, a detectable dNTP substrate, an HIV RT inhibitor, and a ribonucleotide chosen from ATP and GTP or a pyrophosphate. The RT activity is determined by measuring the amount of the detectable dNTP substrate that is incorporated into the template, and the level and/or mechanism of resistance of HIV to the HIV RT inhibitor is determined using the RT activity. The methods may also be used for designing new therapies, screening for new drugs and treatments, and determining the role of mutations in observed resistance.Type: GrantFiled: June 23, 2000Date of Patent: August 8, 2006Inventors: Johan Lennerstrand, Brendan Larder
-
Patent number: 7058616Abstract: A method and system for predicting the resistance of a disease to a therapeutic agent is provided. Further provided is a method and system for designing a therapeutic treatment agent for a patient afflicted with a disease. Specifically, the methods use a trained neural network to interpret genotypic information obtained from the disease. The trained neural network is trained using a database of known or determined genotypic mutations that are correlated with phenotypic therapeutic agent resistance. The present invention also provides methods and systems for predicting the probability of a patient developing a genetic disease. A trained neural network for making such predictions is also provided.Type: GrantFiled: June 8, 2000Date of Patent: June 6, 2006Assignee: Virco BvbaInventors: Brendan Larder, Dechao Wang
-
Publication number: 20050064397Abstract: The present invention relates to a method of for mutation analysis of the HIV pol gene of HIV-1 virions comprising amplifying viral RNA or DNA via nested PCR using outer primers as represented in SEQ ID No: 1 and 2, amplifying said PCR product via nested PCR using a 5? and 3? primer chosen from the inner primers SEQ ID No: 3, 4, 5, and 6, and sequencing this secondary obtained PCR product using at least one sequencing primer chosen from any of SEQ ID No: 7 to 12 or variants thereof. In the alternative, at least one secondary sequencing primer may be used chosen from any of SEQ ID No: 13 to 24. The present invention also relates to kits for performing such a method as well as primers for performing the same.Type: ApplicationFiled: September 8, 2004Publication date: March 24, 2005Inventors: Brendan Larder, Sharon Kemp, Stuart Bloor, Ann Brophy
-
Publication number: 20050058981Abstract: The present invention relates to a method for mutation analysis of the HIV pol gene of HIV virions comprising amplifying virion RNA or DNA via nested PCR using outer primers as represented in SEQ ID No. 1 and 2, amplifying said PCR product via nested PCR using a 5? and 3? primer chosen from the inner primers SEQ ID No. 3, 4, 5, and 6, and sequencing this secondary obtained PCR product using at least one sequencing primer chosen from any of SEQ ID No. 7 to 12 or variants thereof. In the alternative, at least one secondary sequencing primer may be used chosen from any of SEQ ID No. 13 to 24. The benefit of the sequences present in the invention resides in the fact that, with the aid of the oligonucleotides, the sequences of all presently known HIV subtypes and all mutations of the pol gene presently known to yield resistance towards antiretroviral therapy can be determined. The present invention also relates to kits for performing such a method as well as primers for performing the same.Type: ApplicationFiled: April 20, 2001Publication date: March 17, 2005Inventors: Brendan Larder, Sharon Kemp
-
Patent number: 6800463Abstract: The present invention relates to a method of for mutation analysis of the HIV pol gene of HIV-1 virions comprising amplifying viral RNA or DNA via nested PCR using outer primers as represented in SEQ ID No: 1 and 2, amplifying said PCR product via nested PCR using a 5′ and 3′ primer chosen from the inner primers SEQ ID No: 3, 4, 5, and 6, and sequencing this secondary obtained PCR product using at least one sequencing primer chosen from any of SEQ ID No: 7 to 12 or variants thereof. In the alternative, at least one secondary sequencing primer may be used chosen from any of SEQ ID No: 13 to 24. The present invention also relates to kits for performing such a method as well as primers for performing the same.Type: GrantFiled: August 18, 2000Date of Patent: October 5, 2004Assignee: Virco BvbaInventors: Brendan Larder, Sharon Kemp, Stuart Bloor, Ann Brophy
-
Publication number: 20040137436Abstract: The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said samples is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, and a phenotype is determined for the patients sample. Furthermore, methods are provided for predicting a phenotype from a biological sample and for predicting drug or therapy resistance of a patient, a pathogen or a malignant cell.Type: ApplicationFiled: November 24, 2003Publication date: July 15, 2004Inventors: Brendan Larder, Stuart Bloor, Kurt Hertogs, Pascale Alfons Rosa Dehertogh, Rudy Jean Marc Mortier
-
Publication number: 20040073378Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: ApplicationFiled: April 16, 2003Publication date: April 15, 2004Inventors: Pascale Alfons Rosa Dehertogh, Kurt Hertogs, Brendan Larder, Dechao Wang
-
Publication number: 20040033489Abstract: The present invention concerns methods and systems for improving the accuracy of predicting resistance of a disease to a therapy. In one embodiment of the invention, mean and standard deviation (SD) values of fold change in normalized sensitivity, relative to a laboratory wild type standard pathogen or malignant cell are calculated to demonstrate that the patient samples display inherently different degrees of variation in susceptibility to each therapy. In another embodiment, the 2×SD value for each therapy is used as the cut-off between sensitive (within normal susceptible range) and resistant (above normal susceptible range).Type: ApplicationFiled: April 17, 2003Publication date: February 19, 2004Inventors: Brendan Larder, Richard P Harrigan, Kurt Hertogs
-
Patent number: RE39282Abstract: This invention relates to a methodology for assessing the sensitivity of an HIV-1 sample to zidovudine and to diagnostic assays for use in such assessment.Type: GrantFiled: November 12, 2002Date of Patent: September 12, 2006Assignee: SmithKline Beecham CorporationInventors: Brendan A. Larder, Sharon D. Kemp